|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0300 CAD | 0.00% |
|
+50.00% | -25.00% |
| 26/05 | Ovation Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 01/05 | Ovation Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
Medicinal Chemicals and Botanical Products | |||||||||
Pharmaceuticals | 2L | 1L | 61.93T | 1L | 67.89T | ||||
Total Assets | 8L | 1L | 76.89T | 63.9T | 82.82T | ||||
Interest Expense | - | -588 | -31.08T | -49.93T | -50.36T | ||||
CAPEX | - | - | - | - | - | ||||
EBT | -23.94L | -8L | -8L | -5L | -6L | ||||
Gross Profit | 2L | 1L | 54.1T | 85.72T | 58.07T | ||||
D&A | 8.02T | 6.73T | 3.24T | 2.12T | - | ||||
Operating Income | - | - | - | - | - | ||||
Net Income | -23.94L | -8L | -8L | -5L | -6L |
Geographical Revenue Distribution History
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
United States | - | 1L | 28.19T | 1L | 67.88T | ||||
Total Assets | - | 5.5T | 2.2T | - | - | ||||
Canada | 2L | 1.21T | 33.74T | - | - | ||||
Total Assets | 8L | - | - | - | - | ||||
Interest Expense | - | - | - | - | - | ||||
D&A | 8.02T | - | - | - | - | ||||
CAPEX | - | - | - | - | - | ||||
Gross Profit | 2L | - | - | - | - | ||||
Net Income | -23.94L | - | - | - | - | ||||
EBT | -23.94L | - | - | - | - | ||||
Operating Income | - | - | - | - | - |
- Stock Market
- Stocks
- OVAT Stock
- Financials Ovation Science Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
